|1.||Mergen, Hatice: 2 articles (12/2015 - 12/2012)|
|2.||Saglar, Emel: 2 articles (12/2015 - 12/2012)|
|3.||Maghnie, Mohamad: 2 articles (04/2015 - 07/2005)|
|4.||Arima, H: 2 articles (01/2014 - 07/2010)|
|5.||Oiso, Y: 2 articles (01/2014 - 07/2010)|
|6.||Rutishauser, Jonas: 2 articles (02/2011 - 05/2002)|
|7.||Antunes-Rodrigues, Jose: 2 articles (03/2010 - 10/2003)|
|8.||Moreira, Ayrton C: 2 articles (03/2010 - 10/2003)|
|9.||Elias, Paula C L: 2 articles (03/2010 - 10/2003)|
|10.||Elias, Lucila L K: 2 articles (03/2010 - 10/2003)|
|1.||Chronic Kidney Failure (Chronic Renal Failure)
10/01/1987 - "High-performance liquid chromatographic characterization of neurophysins in chronic renal failure."
03/01/1979 - "Plasma neurophysin I and II levels were both significantly elevated in fourteen patients with chronic renal failure and rose over haemodialysis, suggesting that the kidney may be the major route of clearance of the neurophysins. "
|2.||Kidney Diseases (Kidney Disease)
03/01/1978 - "It is shown that the raised levels of neurophysins observed in the serum of some patients with kidney disease are not attributable to a decrease in the urinary clearance of neurophysins."
03/01/1978 - "The increased rate of urinary excretion of neurophysins observed in some patients with kidney disease therefore appears to be related to a disorder of renal tubular function. "
03/01/1978 - "The mean rate of excretion of neurophysins in the urine of 16 patients with kidney disease but without tubular dysfunction was 0.48 +/- 0.14 (S.E.M.) ng/min, whereas the rate in 16 patients with tubular dysfunction was 3.64 +/- 1.56 ng/min (significantly different; 2P less than 0.01). "
03/01/1978 - "Urinary excretion of neurophysins in patients with kidney disease."
|3.||Small Cell Carcinoma
10/01/1980 - "A study of 61 patients with small cell carcinoma of the lung using specific RIAs for 2 human neurophysins (HNPs) has revealed that plasma levels of 1 or both HNPs are substantially elevated (> 3 times) in 62% of the patients before the commencement of therapy. "
11/01/1983 - "In contrast, elevated plasma concentrations of the neurophysins were seen in only 19.6% of 56 patients with non-small cell carcinoma of the lung. "
01/01/1979 - "We concluded that AVP and neurophysins cannot be considered as a good tumoral marker in the detection of oat cell carcinoma of the lung."
01/01/1979 - "No statistically significant difference was noted in the AVP, neurophysins and osmolality values between 10 patients with asymptomatic oat cell carcinoma and control population (10 normal volunteers, 12 patients with non neoplasic lung pathology and 10 patients with different lung carcinoma). "
10/01/1988 - "Neurophysins as tumor markers for small cell carcinoma of the lung. "
|4.||Neurogenic Diabetes Insipidus (Central Diabetes Insipidus)
06/01/2013 - "We characterized the clinical and biochemical features, and sequenced the AVP neurophysin-II(AVP-NPII) gene of the affected individuals with autosomal dominant neurohypophyseal diabetes insipidus(ADNDI)to determine whether this disease was genetically determined. "
09/01/2002 - "A missense mutation encoding Cys73Phe in neurophysin II is associated with autosomal dominant neurohypophyseal diabetes insipidus."
08/01/2001 - "Hyperintensity of posterior pituitary on MR T1WI in a boy with central diabetes insipidus caused by missense mutation of neurophysin II gene."
01/01/2001 - "A missense mutation encoding cys(67) --> gly in neurophysin ii is associated with early onset autosomal dominant neurohypophyseal diabetes insipidus."
11/01/1997 - "Autosomal dominant neurohypophyseal diabetes insipidus associated with a missense mutation encoding Gly23-->Val in neurophysin II."
01/01/1980 - "In this study two approaches have been used: (1) comparison of immunostaining for neurophysin in normal versus homozygous Brattleboro rats with diabetes insipidus (HODI) which lack VPNP, and (2) application of an antiserum to both rat neurophysins absorbed with HODI rat hypothalamic-pituitary extracts which contain only OTNP. "
07/01/2010 - "Familial neurohypophysial diabetes insipidus (FNDI), an autosomal dominant disorder, is mostly caused by mutations in the gene of neurophysin II (NPII), the carrier protein of arginine vasopressin (AVP). "
05/01/2009 - "Familial neurohypophysial diabetes insipidus (FNDI), an autosomal dominant disorder, is mostly caused by mutations in the gene of neurophysin II (NPII), the carrier protein of arginine vasopressin (AVP). "
07/01/2005 - "Molecular biology in selected patients may identify those with apparently idiopathic diabetes insipidus carrying the vasopressin-neurophysin II gene mutation."
05/13/2000 - "Elucidation and identification of the molecular biological alteration in the arginine-vasopressin neurophysin II AVP-NPII gene in a family with familial neurohypophysial diabetes insipidus (FNDI). "
|1.||Neurophysins (Neurophysin I)
|3.||Arginine Vasopressin (Argipressin)
|4.||Vasopressin Receptors (Arginine Vasopressin Receptor)
|5.||Biological Tumor Markers (Tumor Markers)
|7.||Growth Hormone (Somatotropin)
|10.||Oxytocin Receptors (Oxytocin Receptor)
|2.||Heterologous Transplantation (Xenotransplantation)